MENUNews Archive
Date: 05/17/2021
Research suggests stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models and lead to better treatment for non-small cell lung cancer.
Date: 05/06/2021
Oropharyngeal cancer, which occurs in the throat, tonsils, and back of the tongue, has now surpassed cervical cancer as the leading cancer caused by HPV — and 80% of those diagnosed with it are men.
Date: 05/04/2021
This research emphasizes the harms of making colorectal cancer screening independent from cervical cancer screening instead of linking them together as part of important preventative care.
Date: 04/30/2021
The findings suggest policies and public health interventions in Taiwan could help prevent HPV-driven cancers.
Date: 04/26/2021
The Urine Prostate Seq test, or UPSeq for short, uses next-generation genomic sequencing to analyze urine collected from men following a digital rectal exam.
Date: 04/20/2021
The immunotherapy agent pembrolizumab can provide clinical benefit to some patients with metastatic breast cancer whose tumors were found to have a high number of mutations, and whose cancer continued to progress with standard treatments.
Date: 04/17/2021
High expression levels of the gene TRIM63 can serve as an accurate and sensitive biomarker of a subtype of kidney cancer known as microphthalmia-associated transcription factor family aberration-associated renal cell carcinomas — or MiTF renal cell carcinoma.
Date: 04/12/2021
Although clinical guidelines encourage the use of palliative care during end of life care, they aren't being followed for many ovarian cancer patients, particularly for people of color. Palliative care is particularly relevant for people with ovarian cancer because they’re often diagnosed once their cancer has already progressed to an advanced stage. By that point, survival is unlikely; just 17% of those with stage IV ovarian cancer live for at least five years after diagnosis.
Date: 04/01/2021
The findings not only shed new light on cancer immunology, they also suggest clinical trials related to this key target — an interaction that destabilizes the important p53 tumor suppressor protein — may unnecessarily be excluding a large number of patients.
Date: 03/25/2021
A team of researchers from the University of Michigan and the Henry Ford Health System is shedding new light on important differences in triple-negative breast cancer tumors from African, African American and white patients.